3
Participants
Start Date
March 31, 2011
Primary Completion Date
August 31, 2011
Study Completion Date
December 31, 2011
Sorafenib and OSI-906
Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
Emory University Winship Cancer Institute, Atlanta
Ohio State University, Columbus
University of Michigan, Ann Arbor
Collaborators (1)
OSI Pharmaceuticals
INDUSTRY
Emory University
OTHER